Melanotan 2 protocol: Frequently asked questions

Stop dosing immediately if systolic exceeds 140 mmHg or diastolic exceeds 90 mmHg on two consecutive readings separated by 24 hours. Melanotan-2's cardiovascular effects are reversible. Blood pressure normalizes within 48–72 hours of stopping administration. Once readings return to baseline, resume at 50% of the dose that triggered the elevation and extend your titration timeline by two weeks. If blood pressure elevation recurs at the reduced dose, discontinue melanotan-2 entirely. The sympathetic activation is too pronounced for safe continuation.

Hold your current dose for an additional week before increasing. Nausea from melanotan-2 is mediated by MC4 receptor activation in the area postrema (the brain's vomiting center) and typically resolves within 7–10 days as receptor desensitization occurs. If nausea persists beyond two weeks at a stable dose, your titration schedule is too aggressive. Your MC4 receptors aren't desensitizing fast enough to keep pace with dose escalation. Drop back to the previous dose level, hold for two weeks, then resume titration at half the planned increment. Persistent nausea after 40 almost always signals that the peptide is clearing more slowly than anticipated.

Metabolic and receptor changes between 28 and 48 are not linear. They accelerate after 40. A protocol that was safe at 30 can trigger adverse events at 45 even if you're in excellent cardiovascular health. The issue isn't fitness level or body composition; it's receptor density shifts and peptide clearance rate. Treat the modified protocol as the baseline for your current physiology, not as a downgrade from what worked previously. Your melanocortin system has changed. The protocol must change with it.

Melanotan-2 activates hypothalamic MC4R in the arcuate nucleus, producing dose-dependent appetite suppression (20–30% caloric intake reduction at 1mg doses) alongside desire effects—this dual activity is useful for metabolic studies but introduces a confound in pure sexual behavior research. PT-141 activates the same MC4R receptor but at doses (1.75mg) that produce minimal appetite effects in most subjects. If appetite modulation is a study endpoint, Melanotan-2 is the only option. If it's a confound, PT-141 is the cleaner choice.

Reduce the dose to 250mcg for the first 3–5 administrations to allow MC4R receptor desensitization in the area postrema before escalating to 500mcg–1mg therapeutic doses. Nausea incidence drops from 60–70% at 500mcg first-dose to under 30% at 250mcg, and tolerance develops with repeated exposure. Administering Melanotan-2 in the evening reduces nausea impact because subjects sleep through the peak emetic window (60–90 minutes post-injection). PT-141 produces lower nausea incidence overall (40% at 1.75mg), but dose reduction isn't an option because 1.75mg is the established effective dose—switch peptides if nausea is protocol-limiting.

Use PT-141 exclusively—its 100-fold reduced MC1R affinity eliminates melanogenic activity at all clinically relevant doses. Melanotan-2 will produce visible tanning at doses as low as 250mcg when administered repeatedly over 7–10 days, and this effect persists for weeks after peptide clearance because melanin synthesis continues until receptor occupancy normalizes. If your protocol involves repeat dosing or extended observation windows, PT-141 avoids this confound entirely.

Melanotan-2 is the appropriate choice because MC5R activation in penile tissue produces nitric oxide-mediated smooth muscle relaxation independent of hypothalamic desire circuits. PT-141 lacks this peripheral mechanism and will not generate erectile responses unless CNS arousal pathways are activated—it's the wrong tool for isolating peripheral vascular function. Dose Melanotan-2 at 500mcg–1mg subcutaneous and expect spontaneous erections within 2–6 hours in approximately 60–70% of male subjects, with effects persisting 8–12 hours.